Erectile Dysfunction and Exosomes and extracellular vesicles: what the trial registry contains

Why this is studied in Erectile Dysfunction

Erectile dysfunction is usually vascular and endothelial rather than structural, which is why regenerative approaches — cells, exosomes and shockwave adjuncts — target penile blood flow and nerve recovery. Post-prostatectomy nerve injury is a separate problem with a different time course, and the two are frequently blurred together in marketing.

What exosomes means in this table

Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.

The numbers

Every figure below comes from one reproducible query (erectile dysfunction x exosome) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Evidence here is mid-maturity: a handful of Phase 3 or 4 registrations (1 of 5) sit above a much larger early-phase base.

Registrations do not all survive contact with recruitment — 0 completed here, 0 stopped early, giving a 0% attrition rate.

Median planned enrolment is 60 participants (largest single study: 90). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

4 countries host at least one site. Turkey (Türkiye) is the largest single contributor at roughly 40% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Funding profile: 4 academic or hospital sponsors against 1 commercial ones — academic overall, which is worth knowing before reading any single positive report.

• Jumeirah American Clinic — 1 record
• Medipol University — 1 record
• Ankara City Hospital Bilkent — 1 record
• Labbafinejad Medical Center — 1 record
• Institute for the Study of Urological Diseases, Greece — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many exosomes studies for Erectile Dysfunction are recruiting right now?

3 of 5 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is exosomes an approved treatment for Erectile Dysfunction?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 5 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on exosomes for Erectile Dysfunction?

1 of 5 records carry a Phase 3 or Phase 4 label and 0 are marked completed. Registrations run from 2025 to 2026.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.